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Abstract 
Background : Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are the most common bacterial sexually 
transmitted infections (STIs) worldwide. In the absence of affordable point-of-care STI tests, WHO recommends STI 
testing based on risk factors. This study aimed to develop a prediction tool with a sensitivity of > 90% and efficiency 
(defined as the percentage of individuals that are eligible for diagnostic testing) of < 60%.
Methods:   This study offered CT/NG testing as part of a cluster-randomised trial of community-based delivery of 
sexual and reproductive health services to youth aged 16–24 years in Zimbabwe. All individuals accepting STI test-
ing completed an STI risk factor questionnaire. The outcome was positivity for either CT or NG. Backwards-stepwise 
logistic regression was performed with p ≥ 0.05 as criteria for exclusion. Coefficients of variables included in the final 
multivariable model were multiplied by 10 to generate weights for a STI risk prediction tool. A maximum likelihood 
Receiver Operating Characteristics (ROC) model was fitted, with the continuous variable score divided into 15 catego-
ries of equal size. Sensitivity, efficiency and number needed to screen were calculated for different cut-points.
Results: From 3 December 2019 to 5 February 2020, 1007 individuals opted for STI testing, of whom 1003 (99.6%) 
completed the questionnaire. CT/NG prevalence was 17.5% (95% CI 15.1, 19.8) (n = 175). CT/NG positivity was 
independently associated with being female, number of lifetime sexual partners, relationship status, HIV status, self-
assessed STI risk and past or current pregnancy. The STI risk prediction score including those variables ranged from 2 
to 46 with an area under the ROC curve of 0.72 (95% CI 0.68, 0.76). Two cut-points were chosen: (i) 23 for optimised 
sensitivity (75.9%) and specificity (59.3%) and (ii) 19 to maximise sensitivity (82.4%) while keeping efficiency at < 60% 
(59.4%).
Conclusions: The high prevalence of STIs among youth, even in those with no or one reported risk factor, may 
preclude the use of risk prediction tools for selective STI testing. At a cut-point of 19 one in six young people with STIs 
would be missed.
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Introduction
Chlamydia trachomatis and Neisseria gonorrhoeae are 
the most common bacterial sexually transmitted infec-
tions (STIs) worldwide. These conditions have important 
sexual, reproductive, and maternal-child health conse-
quences, including genital symptoms, pregnancy com-
plications, infertility, enhanced HIV transmission, and 
psychological effects [1–8]. Importantly both chlamydia 
and gonorrhoea are curable with well-tolerated short-
course antibiotics.
  In 2016, there were an estimated 127.2 million (95% 
uncertainty interval (UI): 95.1–165.9 million) chlamydia 
and 86.9 million (95% UI: 58.6–123.4 million) gonor-
rhoea infections globally, with prevalence varying by 
World Health Organization (WHO) region [9]. Chla-
mydia prevalence estimates among 15–49 year olds in 
the African region are the second highest globally at 5.0% 
(95% UI: 3.8–6.6) in women and 4.0% (95% UI: 2.4–6.1) 
in men. The African region is estimated to have the high-
est prevalence of gonorrhoea globally with a prevalence 
of 1.9% (95% UI: 1.3–2.7) in women and 1.6% (95% UI: 
0.9–2.6) in men. Systematic reviews focusing on women 
in sub-Saharan Africa revealed a prevalence of chlamydia 
of 3.3–7.8% and gonorrhoea of 2.2–4.2% [10, 11]. How-
ever, comparable data for men are scarce. Notably, youth 
are at much higher risk of STIs than adults [9, 12–14]. 
An individual participant data meta-analysis including 
women participating in 18 HIV prevention studies in 
sub-Saharan Africa recruited mostly before 2010 showed 
that chlamydia and gonorrhoea prevalence was gener-
ally higher among the 15-24 year olds compared to the 
25–49 year olds [15].
The WHO Global Health Sector Strategy on STIs 
2016–2021 (Global Strategy), provides goals, targets, and 
priority actions for curtailing the STI epidemic [16]. A 
priority action for countries is the implementation and 
scale-up of services aimed at early diagnosis of STIs to 
ensure effective medical treatment and prevent further 
transmission. Early diagnosis of STIs is challenging, given 
that most STIs are asymptomatic especially in women 
[17–19]. In the absence of affordable point-of-care tests 
for STIs, universal screening remains rare in resource-
constrained settings. An approach promoted by WHO 
is to offer STI testing to asymptomatic individuals based 
upon risk factors or risk prediction tools [16].
Clinical prediction rules for STIs have been success-
fully developed for high-income settings to allow for a 
so-called “selective screening” approach [20, 21]. This 
approach is aimed at minimising costs associated with 
testing low-risk individuals while detecting most infec-
tions. Thresholds of 60% efficiency (defined as percentage 
of individuals that are eligible for diagnostic testing based 
on predictive criteria) and 90% sensitivity have been pro-
posed as ideal benchmarks for clinical prediction tools in 
the context of STIs [20, 22, 23].
Previous STI risk prediction tools administered by 
healthcare providers in Africa have been developed using 
an ad-hoc approach and were found to have a poor sen-
sitivity; none have been developed specifically for youth 
[19, 24]. We aimed to develop a clinical prediction tool 
for STIs specifically targeting youth in Zimbabwe.
Methods
Study design and setting
This study was nested within a cluster-randomised trial 
(CHIEDZA) of an integrated package of HIV and sexual 
and reproductive health (SRH) services for youth deliv-
ered in community-based settings in Zimbabwe (regis-
tered in clinical trials.gov: NCT03719521). Individuals 
aged 16–24 years living within an intervention cluster are 
eligible to receive an integrated package of SRH services 
including HIV testing, HIV treatment and adherence 
support, contraception, pregnancy testing, syndromic 
management of STIs, menstrual health information and 
products, condoms and general health counselling. Indi-
viduals older than 24 years of age at a repeat visit, who 
were less than 25 years at the first visit are also eligible to 
accessing the services. Testing for gonorrhoea and chla-
mydia was offered to all clients accessing CHIEDZA ser-
vices over a limited period of time.  Treatment of STIs 
and HIV is provided according to national guidelines. All 
services are offered free of charge.
The trial is being conducted in three provinces (Harare, 
Mashonaland East and Bulawayo), with each province 
containing eight geographically demarcated clusters ran-
domised 1:1 to four intervention and four standard of 
care (routine, existing services) clusters. The intervention 
is delivered once weekly (on the same day each week) at a 
community centre in each intervention cluster by a team 
of nurses, community health workers, youth workers and 
a counsellor.
This sub-study assessing STI risk factors was conducted 
in eight intervention clusters in Harare and Mashonaland 
East.
STI testing
All individuals accessing CHIEDZA services were non-
selectively offered testing for gonorrhoea and chlamydia 
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if they had not tested within the 6 months prior to the 
visit, regardless of whether they had symptoms or risk 
factors for STIs. Those who accepted testing were asked 
to provide a urine sample which was tested using the 
GeneXpert platform (Cepheid, Sunnyvale, CA, USA) 
[9]. All individuals were given the option to pick up their 
result the following week, and individuals with a positive 
result were actively contacted by phone and asked to visit 
the centre. Positive test results were not disclosed over 
the phone, but only provided face to face. Partner notifi-
cation (PN) slips were given to those who had a positive 
STI test result and all partners were offered treatment. 
Individuals who reported STI symptoms were treated 
according to national guidelines for syndromic manage-
ment but were also offered testing for gonorrhoea and 
chlamydia [25].
Risk factors for STIs
All individuals accepting STI testing were approached by 
the study team and asked if they would like to participate 
in the risk factor sub-study. Those consenting were asked 
to answer a short questionnaire (11 items) regarding 
current relationship status, number of sexual partners, 
concurrent partners, condom use, use of contraception, 
previous or current pregnancies and STI risk percep-
tion. HIV status was obtained from the CHIEDZA data-
set. The questions in the questionnaire were informed 
by studies developing risk prediction tools for chlamydia 
and gonorrhoea infection in high-income settings [20, 
21] and studies investigating risk factors for those infec-
tions in sub-Saharan Africa [13, 17, 19, 24, 26, 27]. The 
questionnaire was administered by a research assistant 
not involved in STI testing or delivering other CHIEDZA 
services.
Data analysis
The outcome was positivity for either C. trachomatis or 
N. gonorrhoeae, combined as one variable. For variables 
that only applied to women (past pregnancy and use of 
hormonal contraception) males were coded ‘no’ for mul-
tivariable analysis. Univariable logistic regression was 
used to estimate the odds ratios (OR) and 95% confidence 
intervals (95% CI) for the association between STI infec-
tion and each of the 11 risk factors determined by the 
questionnaire and HIV status, age and sex. Variables that 
were associated with the outcome at 10% significance 
level in the univariable analysis were included in a mul-
tivariable model and then removed sequentially using 
backwards stepwise logistic regression until all remaining 
variables were associated with the outcome at < 5% sig-
nificance. For ordinal variables p-values were calculated 
with a Wald test. Coefficients of variables included in the 
final multivariable model were multiplied by 10 to gen-
erate weights, and the weights were added for each indi-
vidual to create an STI risk score. A maximum likelihood 
Receiver Operating Characteristic (ROC) model was fit-
ted, with the continuous score variable divided into 15 
categories of equal size. All possible cut-points of the risk 
prediction tool were evaluated for sensitivity, specificity, 
efficiency (proportion of the sample who screen positive) 
and number needed to test to obtain one positive result.
From a pilot study, the prevalence of the outcome was 
estimated at 17% [28]. A sample size of 1000 gave 80% 
power to detect a risk ratio of 1.7 for a risk factor with 
10% prevalence, and 80% power to detect a risk ratio of 
2.0 for a risk factor with 5% prevalence.
Results
Between 3 December 2019 and 5 February 2020; 1007 
individuals opted for STI testing of whom 1003 gave 
consent for data on risk factors to be collected. The 
majority of these were female (78.7%, n = 789) and aged 
20–24 (58.2%, n = 584) years, similar to the demographic 
profile of those accessing CHIEDZA services. HIV sta-
tus was known for 957 participants, among whom HIV 
prevalence was 5.2% (n = 50). Of these, 36 (72.0%) were 
previously diagnosed and taking antiretroviral therapy 
(ART), and 14 (28.0%) were newly diagnosed through 
CHIEDZA.
Prevalence of C. trachomatis and/or N. gonorrhoeae 
infection was 17.5% (95% CI 15.1–19.8) (n = 175), of 
whom 14.8% (95% CI 12.6–17.1) (n = 148) tested posi-
tive for C. trachomatis and 4.1% (n = 41) (95% CI 2.9–5.5) 
for N. gonorrhoeae, with 1.4% (n = 14) testing positive for 
both infections. In total 39 of the 1003 participants (3.8%) 
reported STI symptoms and 21 received syndromic man-
agement, of whom 13 subsequently tested positive for 
either C. trachomatis, N. gonorrhoeae or both.
In univariable analysis, older age, being female, being 
in a relationship or widowed/divorced, number of life-
time sexual partners and number of sexual partners in 
the past three months, having had a new sexual partner 
in the past three months, history of STI treatment, his-
tory of STI treatment of the partner, occasional condom 
use, perceived high STI risk, positive HIV status and past 
or current pregnancy were all associated with having an 
STI (p < 0.1; Table  1). The multivariable analysis includ-
ing all these variables showed an independent significant 
association between STI infection and being female, rela-
tionship status, number of lifetime sexual partners, HIV 
status, perceived STI risk and past or current pregnancy. 
These variables were included in the final multivariable 
model. Odds ratios for associations between risk fac-
tors and having an STI ranged between 1.23 and 3.98 
(Table 1).
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Table 1 Logistic regression models for association of risk factors with STI prevalence
Multivariable Model 1: includes all potential risk factors and Multivariable Model 2: includes potential risk factors that were associated with STI infection in Model 1 ( 
female gender, relationship status, number of lifetime sexual partners, HIV status, perceived STI risk and past/current pregnancy)
Variable N with STI/ 
total N (STI 
prevalence)




OR (95% CI) p OR p OR p
Age group 16–19 61/419 (14.6) 1 0.042 1 0.95
20–25 114/584 (19.5) 1.42 (1.01, 2.00) 1.01 (0.68, 
1.51)
Sex Male 23/214 (10.8) 1 0.004 1 0.001 1 0.001
Female 152/789 (19.3) 1.98 (1.24, 3.16) 2.77 (1.54, 
4.98)
2.64 (1.52, 4.57)
Relationship status Single 21/177 (11.9) 0.65 (0.39, 1.10) 0.005 1.48 (0.72, 
3.04)
0.02 1.23 (0.67–2.27) 0.007
Boyfriend/girlfriend 70/368 (19.0) 1.14 (0.80, 1.64) 1.82 (1.05, 
3.12)
1.70 (1.09–2.63)
Married 74/434 (17.1) 1 1 1
Divorced/widowed 10/24 (41.7) 3.47 (1.49, 8.12) 4.10 (1.50, 
11.25)
3.71 (1.51–9.06)
New partner in the last 
3 months
Yes 35/157 (22.3) 1.45 (0.95, 2.20) 0.083 0.69 (0.36, 
1.30)
0.25
No 129/846 (16.6) 1 1
No of sexual partners in last 
3 months
0 31/293 (10.6) 1  < 0.001 1 0.16
1 119/623 (19.1) 2.00 (1.31, 3.04) 1.07 (0.54, 
2.12)
2+ 25/87 (28.7) 3.41 (1.88, 6.18) 2.09 (0.83, 
5.25)
No of lifetime partners 0 11/186 (5.9) 1 1 0.004 1
1 54/388 (13.9) 2.57 (1.31, 5.04)  < 0.001 2.19 (0.85, 
5.64)
2.09 (0.98, 4.44)  < 0.001
2 + 110/429 (25.6) 5.49 (2.87, 10.47) 3.89 (1.47, 
10.29)
3.98 (1.93, 8.19)
History of STI treatment Yes 22/79 (27.9) 1.94 (1.15, 3.28) 0.012 0.75 (0.40, 
1.40)
0.36
No 153/924 (16.6) 1 1
Partner ever had an STI Yes 17/43 (39.5) 3.32 (1.76,6.26)  < 0.001 1.90 (0.88, 
4.07)
0.10
No 158/960 (16.5) 1 1
HIV status (N = 957) Positive 18/50 (36.0) 2.79 (1.53, 5.11)  < 0.001 2.05 (1.05, 
4.01)
0.04 1.95 (1.02, 3.72) 0.04
Negative 152/907 (16.8) 1 1 1
Use of condoms (N = 817) Always 15/116 (12.9) 0.70 (0.38, 1.28) 0.004 0.65 (0.32, 
1.35)
0.12
Sometimes 82/319 (25.7) 1.63 (1.13, 2.34) 1.27 (0.81, 
1.99)
Never 67/382 (17.5) 1 1
Perceived STI risk None/low 93/721 (12.9) 1  < 0.001 1 0.01 1  < 0.001
Medium/high 82/282 (29.1) 2.77 (1.98, 3.88) 1.67 (1.12, 
2.49)
1.98 (1.37, 2.87)
Use of hormonal contra-
ception (N = 789)
Yes 87/451 (19.3) 1.00 (0.70, 1.44) 0.98
No 65/338 (19.2) 1
Past or current pregnancy 
(N = 789)
Yes 13/36 (36.1) 2.50 (1.23, 5.05) 0.011 2.70 (1.27, 
5.78)
0.01 2.55 (1.21, 5.39) 0.014
No 139/753 (18.5) 1 1 1
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The STI risk prediction tool generated from the final 
model is shown in Table 2. The score ranged from 2 for 
single participants with no other risk factors to 46 for 
those with all six risk factors (Fig.  1). For example, an 
HIV negative woman with a boyfriend who had 1 lifetime 
sexual partner, perceived herself at low risk and had 
never been pregnant would score 10 + 5 + 7 = 22. The 
maximum possible score for males was 41. A score of 0 
would only be possible for a married male with no life-























Fig. 1 Distribution of STI risk scores. Red bars: tested positive for STI, grey bar: tested negative for STI, red line: efficiency (proportion scoring at or 














Fig. 2 Sensitivity and specificity of all risk score cut-points. Red line: efficiency (proportion scoring at or above the cut-point), grey line: sensitivity, 
blue line specificity, black dotted line: cut-point of 23
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The sensitivity, specificity and efficiency of all pos-
sible cut-points is shown in Fig.  2, and the ROC curve 
with 95% CI is shown in Fig. 3. The area under the curve 
is 0.72. Two cut-points for the risk tool were chosen: 23 
for optimised sensitivity (75.9%) and specificity (59.3%), 
and 19 to meet the benchmark of maximising sensitivity 
(82.4%) while keeping efficiency (59.4%) at less than 60% 
(Table 3). The number needed to screen to diagnose one 
STI was 3.5 for a cut-point of 23 and 4.1 for a cut-point 
of 19.
Discussion
We found a high prevalence of C. trachomatis and/or N. 
gonorrhoeae infection among young people attending a 
community based SRH service in urban and peri-urban 
Zimbabwe. Notably, only 2.1% (21/1003) of participants 
were found to be positive for an STI syndrome and 
treated accordingly. The prevalence of C. trachomatis 
infection was almost three times higher than the WHO 
estimates for the African region, but comparable with 
studies conducted among young women in South Africa 
[9, 26, 29]. The prevalence of N. gonorrhoeae was similar 
to the recent estimates from the Spectrum-STI model for 
Zimbabwe of 3.8% (95% CI 1.8–6.7%) [30].
With non-selective testing the number needed to be 
tested to diagnose an STI was 5.7. This decreased to 4.1 
using an STI risk prediction tool cut-point of 19 and 3.5 
for a risk prediction tool cut-point of 23. While the STI 
risk prediction tool with a cut-point of 19 had the desired 
efficiency of < 60%, the sensitivity was suboptimal at 82%. 
This is because the prevalence of STIs even among cli-
ents with the lowest possible STI risk in this population 
was relatively high. For example STI prevalence was 5.9% 
among those who reported that they had never had sex 
and 13.9% among those who only had one lifetime sexual 
partner. The high STI prevalence among young people 
without reported risk factors in this population suggests 
that non-selective testing may be more appropriate than 
applying a risk prediction tool.
Many recently-published studies show high preva-
lence of STIs in general African populations but none 
has developed a risk prediction tool [13, 17, 26, 27, 29, 
31]. To our knowledge, this is the first study globally that 
has attempted to develop a risk prediction tool in youth, 
who are a high-risk group for these STIs. A recent Ken-
yan study among men who have sex with men developed 
a risk tool for anorectal C. trachomatis and/or N. gonor-
rhoeae infection reaching a sensitivity of 86% at an effi-
ciency of 61% [32]. The proposed risk tool came close to 
the ideal benchmarks for clinical prediction rule perfor-
mance for STIs of > 90% sensitivity and < 60% efficiency 
[20, 22, 23]. The only study examining the performance 
of STI risk prediction tools among African women was 
conducted in 1994 in Tanzania and reported sensitivities 
between 10 and 29% which are inadequate [24].
A recent study enrolling Rwandan women in 2016–
2017 compared the performance of a new diagnostic 
algorithm (‘WISH’ algorithm) with reference standard 
diagnostic testing [19]. The WISH algorithm was pre-
defined at the start of the study; women were consid-
ered positive according to the algorithm if they met one 
or more of the following criteria: currently pregnant, 
exchanged sex for money or goods in the past 12 months, 
new sexual partner in the past 3 months, or vaginal dis-
charge with an offensive smell or pelvic inflammatory 
disease observed by a physician. The prevalence of C. 
trachomatis and/or N. gonorrhoeae was 14% using vagi-
nal swabs investigated by GeneXpert and the sensitivity 
and efficiency of the WISH algorithm was 75% and 56% 
respectively. While the population in the WISH study 
is not truly comparable to our study, low sensitivities of 
both the WISH algorithm and our risk prediction tool 
would result in missing one in four individuals with STIs 
using the WISH algorithm and one in six using our risk 
prediction tool.
A previous study conducted in the same population in 
Zimbabwe found that only 0.5% of youth were treated 
for a STI syndrome and less than 5% reported symptoms 
Table 2 STI risk score variable weightings for variables with p < 0.10 in the final multivariable logistic regression model
β-Coefficient Weighting
Sex Female 0.97 10
Relationship status (vs. married) Single 0.21 2
Boyfriend/girlfriend 0.53 5
Divorced/widowed 1.31 13
Number of lifetime partners (vs. 0) 1 0.74 7
≥ 2 1.38 14
HIV status Positive 0.67 7
Perceived risk of STI Medium/high 0.68 7
Past pregnancy Yes 0.94 9
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when asked specifically [28]. Given the low prevalence 
of reported symptoms, questions about symptoms were 
not included in the questionnaire. However the ques-
tionnaire used in this study included a broad range of 
possible risk factors and was informed by studies inves-
tigating risk factors for STIs in Africa and STI risk pre-
diction tools developed for high income settings [13, 17, 
19–21, 24, 26, 27]. Questions about sexual behaviour are 
often subject to social desirability bias resulting in under- 
or mis-reporting [33–35]. This may limit the sensitivity 
of risk prediction tools based on questions about sexual 
behaviour. While computer-assisted survey instruments 
rather than self- or interviewer-administered question-
naires may reduce social desirability bias, these may be 
more difficult to implement in low-resource settings 
[33–35].
Unsurprisingly STI risk factors in this study were 
closely associated with each other and with the presence 
of C. trachomatis and/or N. gonorrhoeae infection in uni-
variable analysis. Due to the co-linearity of risk factors 
only six independent risk factors were included in the 
multivariable analysis. The model that was developed 
was applicable to both sexes even though one risk factor, 
pregnancy, only applied to women. A sensitivity analysis 
restricted to women resulted in the same five risk factors 
for predicting STIs, which is reassuring regarding the 
robustness of the model. However, we could not conduct 
a sensitivity analysis for men only given the limited num-
ber of men in the study (n = 214). This is a limitation of 
our study, but reflects the reality that men are less likely 
to access services [36, 37].
The strengths of this study include the large sample size 
and high participation rate among those opting for STI 
testing. Also the study was embedded within a popula-
tion-based SRH service offered in eight communities in 
two provinces accessed by youth without pre-selection 
on the basis of STI risk, which makes the findings gen-
eralisable to similar settings. We focused on two highly 
prevalent STIs that cause significant morbidity and mor-
tality. However, we did not include Trichomonas vagi-
nalis, which is highly prevalent especially in women in 
sub-Saharan Africa [13, 26, 38]. Also for logistic reasons 
we used urine instead of vaginal swabs. This may have 
resulted in some STIs being missed.
Importantly we decided against a test and train 
approach, which is usually used when developing risk 
prediction tools [39]. This is because our analysis dem-
onstrated that even the most optimal risk prediction tool 
with a cut-point of 19 was unacceptable.
In view of the high prevalence of STIs among youth in 
sub-Saharan Africa, non-selective diagnostic testing as 
opposed to selective testing following the application of a 
risk prediction tool seems the most promising and appro-
priate approach. This approach will require true point-of-
care STI diagnostics, which are currently available only 
for Trichomonas vaginalis and syphilis [40, 41]. While the 
GeneXpert platform for C. trachomatis and N. gonorrhoeae 
testing does not require expert skills, is easy to use and 
widely available in sub-Saharan Africa, the time to result 
(90 min) is prohibitive for the test to be used as a true point-
of-care test [42]. However, other molecular tests for chla-
mydia and gonorrhoea with rapid time to results (30 min) 
have been successfully trialled in high-income settings [43]. 
Universal point-of-care STI testing and immediate single 
dose treatment for those testing positive should be consid-
ered as a strategy for curbing the STI epidemic in youth.
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